Skip to main content
BU

Bio Usawa

Bio Usawa Inc. manufactures affordable monoclonal antibodies in Africa, focusing on oncology, immunology, and ophthalmology, to provide lifesaving treatments at one-tenth the cost of similar therapies in the United States. By establishing local production capabilities, the company addresses the significant lack of access to effective cancer treatments for patients in Africa.

San Francisco, United States8300+ followers
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Patients in Africa often lack access to life-saving monoclonal antibody therapies due to the high cost of these treatments, which are typically developed and manufactured in advanced economies. This disparity limits access to effective treatments for diseases such as cancer, immunological disorders, and ophthalmological conditions.

Solution

Bio Usawa is addressing this critical need by establishing local manufacturing capabilities in Africa to produce affordable biosimilars and bio-betters of impactful monoclonal antibody therapies. By focusing on local production, Bio Usawa aims to reduce the cost of these treatments to approximately one-tenth of the price in the United States, ensuring accessibility for patients across the continent. The company is committed to developing and delivering high-quality biologics, prioritizing underserved patient populations, empowering African talent, and closing healthcare gaps with life-saving medicines. Bio Usawa's vision is to make Africa a manufacturing powerhouse and exporter of high-quality and affordable biologics, setting a new global standard in healthcare innovation.

Target Audience

The primary target audience includes patients in Africa suffering from diseases treatable with monoclonal antibody therapies, as well as healthcare providers and organizations seeking affordable and accessible treatment options.

Features

  • Development and manufacturing of biosimilars and bio-betters for oncology, immunology, and ophthalmology
  • Local production in Africa to significantly reduce treatment costs
  • Focus on monoclonal antibody therapies
  • Commitment to quality and affordability
  • Partnerships with African organizations to strengthen regulatory frameworks and build local capacity
  • GMP manufacturing
This profile is AI-generated and may contain inaccuracies.